Vaccine hesitancy greatest threat in overcoming Covid: Adar Poonawalla

Serum Institute of India CEO Adar Poonawalla on Wednesday termed vaccine hesitancy as the greatest threat in overcoming the COVID-19 pandemic while urging all adults to get vaccinated at the earliest

Adar Poonawalla, CEO, Serum Institute
Adar Poonawalla, CEO, Serum Institute of India
Press Trust of India New Delhi
2 min read Last Updated : Nov 17 2021 | 10:50 PM IST

Serum Institute of India CEO Adar Poonawalla on Wednesday termed vaccine hesitancy as the greatest threat in overcoming the COVID-19 pandemic while urging all adults to get vaccinated at the earliest.

He said that 200 million doses of the COVID-19 vaccine were lying with the states and people should get themselves vaccinated as soon as possible.

"The vaccine industry has worked tirelessly to provide enough stocks for the nation. Today there are over 200 million doses available with states. I urge all adults to get vaccinated as soon as possible. Vaccine hesitancy is now the greatest threat in overcoming this pandemic," Poonawalla said in a tweet.

Earlier in the day Union Health Minister Mansukh Mandaviya also appealed to all eligible citizens to get vaccinated.

The cumulative COVID-19 vaccines administered in the country has exceeded 113.68 crore mark. Of all the vaccine doses administered, around 90 per cent are Serum's Covishield and close to 10 per cent are Bharat Biotech's Covaxin.

The number of fully vaccinated individuals against COVID-19 has surpassed the partially vaccinated eligible population for the first time in India.

The country has in total administered over 113.68 crore doses, according to the provisional report at 7 am.

This has been achieved through 1,16,73,459 sessions. Out of which, 75,57,24,081 doses were administered as the first dose and 38,11,55,604 doses were administered as second dose. The number of fully vaccinated individuals (38,11,55,604) exceeds those who have been administered a single dose (37,45,68,477).

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccineVaccinationSerum Institute of India

First Published: Nov 17 2021 | 10:50 PM IST

Next Story